Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9 Thoracic 7 Gynecologic 6 Other hematologic neoplasm 5 Genitourinary 5 Breast 5 Lymphoid 3 Tumor-Agnostic 2 Other solid neoplasm 2 Plasma cell 1 Head & Neck 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 181 Nivolumab 117 Ipilimumab 97 Dacarbazine 48 trametinib 37 dabrafenib 35 3-ingenyl angelate 35 Vemurafenib 33 cemiplimab 27 atezolizumab 24 Temozolomide 24 binimetinib 23 Paclitaxel 22 Imiquimod 22 encorafenib 17 avelumab 17 Carboplatin 17 Aminolevulinic Acid 17 spartalizumab 16 cobimetinib 16 Cyclophosphamide 15 Cisplatin 15 Fluorouracil 14 talimogene laherparepvec 13 HhAntag691 11 Gels 11 Drug Therapy 11 Bevacizumab 11 lenvatinib 10 durvalumab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Saline Solution × Dermatologic × Clear all

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡